Adult antiretroviral therapy guidelines 2014

Southern African Journal of HIV Medicine

Volumn 15, Issue 4, 2014, Pages 121-143

  Meintjes, G ^a   Black, J ^a   Conradie, F ^a   Cox, V ^a   Dlamini, S ^a   Fabian, J ^a   Maartens, G ^a   Manzini, T ^a   Mathe, M ^a   Menezes, C ^a   Moorhouse, M ^a   Moosa, Y ^a   Nash, J ^a   Orrell, C ^a   Pakade, Y ^a   Venter, F ^a   Wilson, D ^a   Southern African HIV Clinicians Society, ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ATAZANAVIR; DARUNAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ETRAVIRINE; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; INDINAVIR; INTEGRASE INHIBITOR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RALTEGRAVIR; RILPIVIRINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ACUTE DISEASE; ACUTE KIDNEY FAILURE; ALLERGIC REACTION; ANEMIA; ANTIRETROVIRAL THERAPY; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; BLOOD TOXICITY; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CENTRAL NERVOUS SYSTEM DISEASE; CONFUSION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG TREATMENT FAILURE; DYSGLYCEMIA; DYSLIPIDEMIA; GASTROINTESTINAL SYMPTOM; GYNECOMASTIA; HAIR LOSS; HEALTH CARE QUALITY; HEMODIALYSIS; HEPATITIS; HEPATITIS B; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPERLACTATEMIA; HYPERPIGMENTATION; JAUNDICE; KIDNEY FAILURE; LABORATORY TEST; LIFE EXPECTANCY; LIPOATROPHY; LIVER TOXICITY; MALARIA; MIXED INFECTION; MOOD DISORDER; MORTALITY; MYOPATHY; NAUSEA; NEPHROLITHIASIS; NEPHROTOXICITY; NEUTROPENIA; PANCREATITIS; PERIPHERAL NEUROPATHY; POST EXPOSURE PROPHYLAXIS; PRACTICE GUIDELINE; PROTEINASE INHIBITION; PSYCHOSIS; PURE RED CELL ANEMIA; QUALITY OF LIFE; RHABDOMYOLYSIS; VIRUS LOAD; VIRUS REPLICATION; WASTING SYNDROME; WORLD HEALTH ORGANIZATION;

EID: 84921817100     PISSN: 16089693     EISSN: 20786751     Source Type: Journal    
DOI: 10.7196/SAJHIVMED.1130     Document Type: Article

References (63)

1. Johnson LF, Mossong J, Dorrington RE, et al. International Epidemiologic Databases to Evaluate AIDS Southern Africa Collaboration. Life expectancies of South African adults starting antiretroviral treatment: Collaborative analysis of cohort studies. PLoS Med 2013;10(4):e1001418. [http://dx.doi.org/0.1371/journal.pmed.1001418]
2. Severe P, Juste MA, Ambroise A, et al. Early v. standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J Med 2010;363(3):257-265. [http://dx.doi.org/10.1056/NEJMoa0910370]
3. Writing Committee for the CASCADE Collaboration. Timing of HAART initiation and clinical outcomes in human immunodeficiency virus type 1 seroconverters. Arch Intern Med 2011;171(17):1560-1569. [http://dx.doi.org/10.1001/archinternmed.2011.401]
4. Cain LE, Logan R, Robins JM, et al. When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: An observational study. Ann Intern Med 2011;154(8):509-515. [http://dx.doi.org/10.7326/0003-4819-154-8-201104190-00001]
5. Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early v. deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009;360(18):1815-1826. [http://dx.doi.org.10.1056/NEJMoa0807252]
6. Sterne JA, May M, Costagliola D, et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: A collaborative analysis of 18 HIV cohort studies. Lancet 2009;373(9672):1352-1363. [http://dx.doi.org/10.1016/S0140-6736(09)60612-7]
7. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011;365(6):493-505. [http://dx.doi.org/0.1056/NEJMoa1105243]
8. Tanser F, Bärnighausen T, Grapsa E, Zaidi J, Newell ML. High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa. Science 2013;339(6122):966-971. [http://dx.doi.org/10.1126/science.1228160]
9. Petersen ML, Wang Y, van der Laan MJ, Rhee SY, Shafer RW, Fessel WJ. Virologic efficacy of boosted double versus boosted single protease inhibitor therapy. Aids 2007;21(12):1547-1554. [http://dx.doi.org/10.1097/QAD.0b013e32825a69a8]
10. Badri M, Ehrlich R, Wood R, Pulerwitz T, Maartens G. Association between tuberculosis and HIV disease progression in a high tuberculosis prevalence area. Int J Tuberc Lung Dis 2001;5(3):225-232.
11. Abdool Karim SS, Naidoo K, Grobler A, et al. Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med 2011 365(16):1492-1501. [http://dx.doi.org/10.1056/NEJMoa1014181]
12. Blanc FX, Sok T, Laureillard D, et al. Earlier v. later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med 2011;365(16):1471-1481. [http://dx.doi.org/10.1056/NEJMoa1013911]
13. Havlir DV, Kendall MA, Ive P, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med 2011;365(16):1482-1491. [http://dx.doi.org/10.1056/NEJMoa1013607]
14. Mfinanga SG, Kirenga BJ, Chanda DM, et al. Early v. delayed initiation of highly active antiretroviral therapy for HIV-positive adults with newly diagnosed pulmonary tuberculosis (TB-HAART): A prospective, international, randomised, placebo-controlled trial. Lancet Infect Dis 2014;14(7):563-571. [http://dx.doi.org/10.1016/S1473-3099(14)70733-9]
15. Török ME, Yen NT, Chau TT, et al. Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)-associated tuberculous meningitis. Clin Infect Dis 2011;52(11):1374-1383. [http://dx.doi.org/10.1093/cid/cir230]
16. Zolopa A, Andersen J, Powderly W, et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: A multicenter randomized strategy trial. PLoS One 2009;4(5):e5575. [http://dx.doi.org/10.1371/journal.pone.0005575]
17. Boulware DR, Meya DB, Muzoora C, et al. Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis. N Engl J Med 2014;370(26):2487-2498. [http://dx.doi.org/10.1056/NEJMoa1312884]
18. Saez-Cirion A, Bacchus C, Hocqueloux L, et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathogens 2013;9(3):e1003211. [http://dx.doi.org/10.1371/journal.ppat.1003211]
19. Riddler SA, Haubrich R, DiRienzo AG, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008;358(20):2095-2106. [http://dx.doi.org/10.1056/NEJMoa074609]
20. Cohen CJ, Molina JM, Cassetti I, et al. Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials. Aids 2013;27(6):939-950. [http://dx.doi.org/10.1097/QAD.0b013e32835cee6e]
21. Molina JM, Clumeck N, Orkin C, et al. Week 96 analysis of rilpivirine or efavirenz in HIV-1-infected patients with baseline viral load
22. ENCORE1 Study Group, Puls R, Amin J, et al. Efficacy of 400 mg efavirenz v. standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): A randomised, double-blind, placebo-controlled, non-inferiority trial. Lancet 2014;383(9927):1474-1482. [http://dx.doi.org/10.1016/S0140-6736(13)62187-X]
23. Post FA, Moyle GJ, Stellbrink HJ, et al. Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine v. tenofovir/emtricitabine, administered with efavirenz, in antiretroviralnaive, HIV-1-infected adults: 48-week results from the ASSERT study. J Acquir Immune Defic Syndr 2010;55(1):49-57. [http://dx.doi.org/10.1097/QAI.0b013e3181dd911e]
24. Sax PE, Tierney C, Collier AC, et al. Abacavir-lamivudine v. tenofoviremtricitabine for initial HIV-1 therapy. N Engl J Med 2009;361(23):2230-2240. [http://dx.doi.org/10.1056/NEJMoa0906768]
25. Cruciani M, Mengoli C, Malena M, et al. Virological efficacy of abacavir: Systematic review and meta-analysis. J Antimicrob Chemother 2014;69(12):3169-3180. [http://dx.doi.org/10.1093/jac/dku279]
26. Ribaudo HJ, Benson CA, Zheng Y, et al. No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: Short and long-term results from ACTG A5001/ALLRT. Clin Infect Dis 2011;52(7):929-940. [http://dx.doi.org/10.1093/cid/ciq244]
27. Sabin CA, Worm SW, Weber R, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: A multi-cohort collaboration. Lancet 2008;371(9622):1417-1426. [http://dx.doi.org/10.1016/S0140-6736(08)60423-7]
28. Cruciani M, Zanichelli V, Serpelloni G, et al. Abacavir use and cardiovascular disease events: A meta-analysis of published and unpublished data. AIDS 2011;25(16):1993-2004. [http://dx.doi.org/10.1097/QAD.0b013e328349c6ee]
29. Ford N, Meintjes G, Pozniak A, et al. The future role of CD4 cell count for monitoring antiretroviral therapy. Lancet Infect Dis. Published online 19 Nov 2014. [http://dx.doi.org/10.1016/S1473-3099(14)70896-5]
30. Rawizza HE, Chaplin B, Meloni ST, et al. Immunologic criteria are poor predictors of virologic outcome: Implications for HIV treatment monitoring in resource-limited settings. Clin Infect Dis 2011;53(12):1283-1290. [http://dx.doi.org/10.1093/cid/cir729]
31. Manasa J, Katzenstein D, Cassol S, Newell ML, de Oliveira T. Primary drug resistance in South Africa: Data from 10 years of surveys. AIDS Res Hum Retroviruses 2012;28(6):558-565. [http://dx.doi.org/10.1089/aid.2011.0284]
32. Smith CJ, Sabin CA, Lampe FC, et al. The potential for CD4 cell increases in HIV-positive individuals who control viraemia with highly active antiretroviral therapy. AIDS 2003;17(7):963-969. [http://dx.doi.org/10.1097/01.aids.0000060352.78202.79]
33. Guihot A, Tubiana R, Breton G, et al. Immune and virological benefits of 10 years of permanent viral control with antiretroviral therapy. AIDS 2010;24(4):614-617. [http://dx.doi.org/10.1097/QAD.0b013e32833556f3]
34. Kaufmann GR, Furrer H, Ledergerber B, et al. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/μL in HIV type 1-infected individuals receiving potent antiretroviral therapy. Clin Infect Dis 2005;41(3):361-372. [http://dx.doi.org/10.1086/431484]
35. Mocroft A, Phillips AN, Gatell J, et al. Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: An observational cohort study. Lancet 2007;370(9585):407-413. [http://dx.doi.org/10.1016/S0140-6736(07)60948-9/10.1016/S0140-6736(07)60948-9]
36. + cell count <200 cells per cubic millimeter at 2 years after initiation of combination antiretroviral therapy is associated with increased mortality in HIV-infected individuals with viral suppression. J Acquir Immune Defic Syndr 2010;55(4):451-459.
37. Tuboi SH, Pacheco AG, Harrison LH, et al. Mortality associated with discordant responses to antiretroviral therapy in resource-constrained settings. J Acquir Immune Defic Syndr 2010;53(1):70-77. [http://dx.doi.org/10.1097/QAI.0b013e3181c22d19]
38. Ledergerber B, Lundgren JD, Walker AS, et al. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet 2004;364(9428):51-62. [http://dx.doi.org/10.1016/S0140-6736(04)16589-6]
39. Paton NI, Kityo C, Hoppe A, et al. Assessment of second-line antiretroviral regimens for HIV therapy in Africa. N Engl J Med 2014;371(3):234-247. [http://dx.doi.org/10.1056/NEJMoa1311274]
40. Johnson M, Grinsztejn B, Rodriguez C, et al. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS 2006;20(5):711-718. [http://dx.doi.org/10.1097/01.aids.0000216371.76689.63]
41. Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. J Acquir Immune Defic Syndr 2010;53(3):323-332. [http://dx.doi.org/10.1097/QAI.0b013e3181c990bf]
42. Hamers R, Sigaloff K, Wallis C, et al.; and PharmAccess African Studies to Evaluate Resistance (PASER). Patterns of HIV-1 Drug-Resistance after First-line ART Failure and Response to Second-line ART in a Multi-country Cohort: Sub-Saharan Africa. 19th Conference on Retroviruses and Opportunistic Infections. Seattle, 5-8 March 2012. Abstract 104.
43. Yazdanpanah Y, Fagard C, Descamps D, et al. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: Results of the ANRS 139 TRIO trial. Clin Infect Dis 2009;49(9):1441-1449. [http://dx.doi.org/10.1086/630210]
44. Arastéh K, Yeni P, Pozniak A, et al. Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96. Antivir Ther 2009;14(6):859-864. [http://dx.doi.org/10.3851/1301]
45. Steigbigel RT, Cooper DA, Teppler H, et al. Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatmentexperienced patients with drug-resistant HIV infection: Week 96 results of the BENCHMRK 1 and 2 Phase III trials. Clin Infect Dis 2010;50(4):605-612. [http://dx.doi.org/10.1086/650002]
46. Lazzarin A, Campbell T, Clotet B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007;370(9581):39-48. [http://dx.doi.org/10.1016/S0140-6736(07)61048-4]
47. Madruga JV, Cahn P, Grinsztejn B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007;370(9581):29-38. [http://dx.doi.org/10.1016/S0140-6736(07)61047-2]
48. Stevens WS, Wallis CL, Sanne I, Venter F. Will etravirine work in patients failing non-nucleoside reverse transcriptase inhibitor-based treatment in southern Africa? J Acquir Immune Defic Syndr 2009;52(5):655-656. [http://dx.doi.org/10.1097/QAI.0b013e3181ba1b00]
49. + count-guided interruption of antiretroviral treatment. N Engl J Med 2006;355(22):2283-2296. [http://dx.doi.org/10.1056/NEJMoa062360]
50. Wainberg MA, Zaharatos GJ, Brenner BG. Development of antiretroviral drug resistance. N Engl J Med 2011;365(7):637-646. [http://dx.doi.org/10.1056/NEJMra1004180]
51. Davies G, Cerri S, Richeldi L. Rifabutin for treating pulmonary tuberculosis. Cochrane Database Syst Rev 2007;(4):CD005159. [http://dx.doi.org/10.1002/14651858.CD005159.pub2]
52. Bradshaw D, Chopra M, Kerber K, et al. Every death counts: Use of mortality audit data for decision making to save the lives of mothers, babies, and children in South Africa. Lancet 2008;371(9620):1294-1304. [http://dx.doi.org/10.1016/S0140-6736(08)60564-4]
53. Ford N, Calmy A, Mofenson L. Safety of efavirenz in the first trimester of pregnancy: An updated systematic review and meta-analysis. AIDS 2011;25(18):2301-2304. [http://dx.doi.org/10.1097/QAD.0b013e32834cdb71]
54. World Health Organization. Technical update on treatment optimization. Use of efavirenz during pregnancy: A public health perspective. Geneva: World Health Organization, 2012.
55. Patterson KB, Dumond JB, Prince HA, et al. Protein binding of lopinavir and ritonavir during 4 phases of pregnancy: Implications for treatment guidelines. J Acquir Immune Defic Syndr 2013;63(1):51-58. [http://dx.doi.org/10.1097/QAI.0b013e31827fd47e]
56. Eley T, Bertz R, Hardy H, Burger D. Atazanavir pharmacokinetics, efficacy and safety in pregnancy: A systematic review. Antivir Ther 2013;18(3):361-375. [http://dx.doi.org/10.3851/IMP2473]
57. De Waal R, Cohen K, Maartens G. Systematic review of antiretroviral-associated lipodystrophy: lipoatrophy, but not central fat gain, is an antiretroviral adverse drug reaction. PLoS One 2013;8(5):e63623. [http://dx.doi.org/10.1371/journal. pone.0063623]
58. Haddow LJ, Colebunders R, Meintjes G, et al. Cryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: Proposed clinical case definitions. Lancet Infect Dis 2010;10(11):791-802. [http://dx.doi.org/10.1016/S1473-3099(10)70170-5]
59. Meintjes G, Lawn SD, Scano F, et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: Case definitions for use in resourcelimited settings. Lancet Infect Dis 2008;8(8):516-523. [http://dx.doi.org/10.1016/S1473-3099(08)70184-1]
60. Meintjes G, Wilkinson RJ, Morroni C, et al. Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. Aids 2010;24(15):2381-2390. [http://dx.doi.org/10.1097/QAD.0b013e32833dfc68]
61. Meintjes G, Sonderup MW. A practical approach to the diagnosis and management of paradoxical tuberculosis immune reconstitution inflammatory syndrome. Continuing Medical Education 2011;29(10):410-417.
62. Rangaka MX, Wilkinson RJ, Boulle A, et al. Isoniazid plus antiretroviral therapy to prevent tuberculosis: A randomised double-blind, placebo-controlled trial. Lancet 2014;384(9944):682-690. [http://dx.doi.org/10.1016/S0140-6736(14)60162-8]
63. Getahun H, Kittikraisak W, Heilig CM, et al. Development of a standardized screening rule for tuberculosis in people living with HIV in resourceconstrained settings: Individual participant data meta-analysis of observational studies. PLoS Med 2011;8(1):e1000391. [http://dx.doi.org/10.1371/journal.pmed.1000391]